Quantcast

Latest Interferon beta-1a Stories

2008-09-18 09:00:49

Biogen Idec (NASDAQ: BIIB) will present new data on the company's leading multiple sclerosis (MS) franchise at the World Congress on Treatment and Research in Multiple Sclerosis taking place this week in Montreal, Canada. Nearly 20 presentations will focus on the company's products: TYSABRI(R) (natalizumab), which offers MS patients a new level of efficacy, and AVONEX(R) (Interferon beta-1a), the most prescribed MS therapy worldwide, as well as its pipeline featuring compounds targeting...

2008-09-17 09:01:00

Merck KGaA has announced that its Merck Serono division has completed patient enrollment in the Reflex trial of Rebif in patients at risk of developing multiple sclerosis. The randomized, double-blind, placebo-controlled, international Phase III trial is designed to evaluate the therapeutic benefit of Rebif (interferon beta-1a) on the time to conversion to multiple sclerosis (MS) in people with a first clinical event suggestive of the disease. A total of 517 patients considered at risk of...

2008-09-15 09:00:58

Bayer HealthCare Pharmaceuticals Inc. today announced that Betaseron(R)* (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections. "One of the barriers that many people with multiple sclerosis face in starting an MS treatment is...

2008-08-29 06:00:55

Biogen Idec has completed enrollment in the Assurance trial, a long-term follow-up study which will assess up to 15 years of Avonex treatment in an effort to provide detailed data on the long-term efficacy of the drug. Assurance is a multi-center, open-label follow-up study of patients with relapsing multiple sclerosis (MS) treated with Avonex or placebo for at least two years in the Phase III pivotal trial. In the trial, 136 of a possible 172 patients were identified for this study at...

2008-08-27 18:00:56

Biogen Idec today announced that enrollment is complete in the ASSURANCE trial, a long-term follow-up study which will assess up to 15 years of AVONEX(R) (interferon beta-1a) treatment in an effort to provide detailed data on the long term efficacy of the drug. ASSURANCE is a multi-center, open-label follow-up study of patients with relapsing multiple sclerosis (MS) treated with AVONEX or placebo for at least two years in the phase III pivotal trial. In the trial, 136 of a possible 172...

2008-07-23 03:00:22

By Blasier, Mary Gail Key Words: Multiple sclerosis, central nervous system, disease modifying therapies, quality of life. Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), which is composed of the brain, optic nerves, and spinal cord (Graham, 2009). It is thought to be an autoimmune disorder that afflicts approximately 400,000 Americans in early to middle adulthood (ages 20 to 40) (National Multiple Sclerosis Society [NMSS], 2008). About 200 people are newly...

2008-07-16 09:01:19

Teva Pharmaceutical Industries and Active Biotech have announced that patients are being enrolled for the Bravo Phase III pivotal trial. Bravo is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex. The Bravo trial, which was initiated in April, 2008, aims to enroll approximately 1,200...

2006-06-05 16:35:00

By Susan Heavey WASHINGTON (Reuters) - U.S. health officials cleared the way on Monday for multiple sclerosis drug Tysabri to return to the market with restrictions, following its withdrawal last year when it was linked to a rare but potentially fatal brain disease. Three patients taking the drug, made by Biogen Idec Inc. and distributed by Elan Corp., had developed progressive multifocal leukoencephalopathy (PML). Two of them died. Food and Drug Administration officials, who faced calls from...

2006-05-31 02:13:50

LOS ANGELES (Reuters) - Teva Pharmaceutical Industries Ltd. said on Wednesday that its multiple sclerosis drug Copaxone was shown in a clinical trial to be effective in patients who had stopped responding to Avonex, a competing drug made by Biogen Idec. Israel-based Teva said the study of patients with relapsing-remitting MS found that Copaxone reduced their annual relapse rate by an additional 57 percent over Avonex, and that neurologic disability did not worsen in 86 percent of...

2006-04-05 16:15:00

By Deena Beasley LOS ANGELES (Reuters) - A high dose of Teva Pharmaceutical Industries Ltd.'s multiple sclerosis drug Copaxone is more effective at limiting relapses and brain lesions than the standard dose, without more side effects, researchers said on Wednesday. "For some people a higher dose may work better," said Dr. Jeffrey Cohen of the Cleveland Clinic's MS research center and lead investigator of a small nine-month trial comparing the two doses. The study, funded by Israel-based Teva,...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related